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Aims In low-gradient aortic stenosis (LGAS), the high valvulo-arterial impedance observed despite low valvular gradient
suggests a high vascular load. Thoracic aortic calcifications (TACs) and valvular aortic calcifications (VACs) are, re-
spectively, surrogates of aortic load and aortic valvular gradient. The aim of this study was to compare the respect-
ive contributions of TAC and VAC on 3-year cardiovascular (CV) mortality following TAVI in LGAS vs. high-




A total of 1396 consecutive patients were included. TAC and VAC were measured on the pre-TAVI CT-scan.
About 435 (31.2%) patients had LGAS and 961 (68.8%) HGAS. LGAS patients were more prone to have diabetes,
coronary artery disease (CAD), atrial fibrillation (AF), and lower left ventricular ejection fraction (LVEF), P<0.05
for all. During the 3 years after TAVI, 245(17.8%) patients experienced CV mortality, 92(21.6%) in LGAS and
153(16.2%) in HGAS patients, P=0.018. Multivariate analysis adjusted for age, gender, diabetes, AF, CAD, LVEF,
renal function, vascular access, and aortic regurgitation showed that TAC but not VAC was associated with CV
mortality in LGAS, hazard ratio (HR) 1.085 confidence interval (CI) (1.019–1.156), P=0.011, and HR 0.713 CI
(0.439–1.8), P=0.235; the opposite was observed in HGAS patients with VAC but not TAC being associated with
CV mortality, HR 1.342 CI (1.034–1.742), P=0.027, and HR 1.015 CI (0.955–1.079), P=0.626.
...................................................................................................................................................................................................
Conclusion TAC plays a major prognostic role in LGAS while VAC remains the key in HGAS patients. This confirms that
LGAS is a complex vascular and valvular disease.
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Introduction
Low-gradient aortic stenosis (LGAS) is being more and more recog-
nized as a peculiar form of aortic stenosis (AS); it currently repre-
sents 30–50% of patients with severe AS.1,2 The prognosis of LGAS is
worse than that of high-gradient aortic stenosis (HGAS), the
explanation being uncertain.2 In HGAS, the primary abnormality
is valvular impediment represented by mean aortic gradient
>_40 mmHg, a surrogate of which may be valvular aortic calcifications
(VACs).3,4 Despite a lower mean transaortic gradient, LGAS patients
often exhibit a higher left ventricle afterload assessed by valvulo-
arterial impedance.5,6 We have shown that thoracic aortic
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calcifications (TACs), which reflects vascular impediment, are of
prognosis significance after transcatheter aortic valve implantation
(TAVI)7,8; since our initial publications, this has been confirmed by
other groups in other countries.9 We hypothesize that the contribu-
tion of VAC and TAC to the post-TAVI outcome may differ depend-
ing on aortic gradient: from a prevailing valvular disease in HGAS to a
more complex valvular and vascular disease in LGAS.
Thus, the objective of this study was to compare the respective
contribution of TAC and VAC on 3-year cardiovascular (CV) mortal-
ity following TAVI in LGAS as compared with HGAS patients.
Methods
Patients
Among the 1425 patients of the multicentric C4CAPRI study recruited
between 2010 and 2014, 1396 patients with both an available pre-
operative CT-scan and a measurement of mean aortic gradient were
included. The C4CAPRI cohort has been described elsewhere.10 Patients
were indicated for TAVI in the presence of severe AS when surgical aor-
tic valve replacement was either contraindicated or deemed at too high
risk by the multidisciplinary Heart Team. Severe AS was defined by an
aortic valve area <1.0 cm2 (or 0.6 cm2/m2) and/or a mean transaortic
pressure gradient >40 mmHg and/or a peak aortic jet velocity
(Vmax)>4 m/s. Mean aortic gradient was obtained with transthoracic
echography (TTE). TTE was performed by a senior cardiologist, using
continuous Doppler in the most appropriate window among five apical
chamber view, right parasternal, and suprasternal views. LGAS was
defined as a mean aortic gradient<40 mmHg and HGAS as a mean aortic
gradient>_40 mmHg.2 The C4CAPRI study was approved by the ethics
committee (Comité de Protection des Personnes SUD-EST IV, L16-56)
and by the Commission Informatique et Liberté (CNIL N 16-065). All
patients provided written informed consent to anonymous processing of
their data.
Patient and public involvement
Before undergoing the TAVI procedures, patients were asked to give and
sign an informed consent to participate to the registry.
Patients were not involved in the design of the study.
Outcomes
The primary outcome was CV mortality (according to the VARC-2 crite-
ria11) occurring within a 3-year follow-up period after TAVI. Vital status
was obtained by telephone contact with patients, their relatives, carers or
physicians, and by on-site planned visits. A follow-up was censored at 3-
year following TAVR. Two experienced cardiologists blinded to TAC,
VAC, and to patient characteristics adjudicated CV mortality according
to the VARC-2 criteria.11. Data collection was performed through dedi-
cated web-based case report forms in each centre, which were merged
for analysis. Range checks to identify extreme values and assessments of
internal consistency were applied during upload.
Measurement of TAC AND VAC
The way measurements were performed has been described else-
where.10 Briefly, both TAC and VAC were extracted using semi-
automated dedicated software from the CT scanner of the valve and the
whole thoracic aorta with a very good reproducibility as previously
described.10 For each patient, TAC was calculated from the aortic sinus
to the aortic hiatus while excluding VAC, and VAC was measured
including valve leaflets and annular calcification while ignoring non-
valvular calcification in the left ventricular outflow tract, aortic sinus, cor-
onary arteries, and mitral annulus. Figure 1 shows an example of VAC and
TAC measurements.
Statistical analysis
Variables are summarized as means±standard deviations, or numbers
and percentages, as appropriate. Comparisons between LGAS and
HGAS patients were performed using v2 test, unpaired t-test, or non-
parametric test as appropriate. Both TAC and VAC were considered
as categorical variables (three groups according to terciles of TAC
and three groups according terciles of VAC) or continuous variables.
Correlates of TAC and VAC were assessed using univariate and multi-
variate linear regression. Comparisons of distributions of TAC and
VAC among LGAS and HGAS, patients were performed using a
Mann–Whitney non-parametric test and illustrated using box plots.
The prognostic value of the TAC and VAC was first assessed by
building Kaplan–Meier curves of cardiovascular mortality for the
three groups defined according to the terciles of TAC and VAC. The
three curves were compared using the log-rank test.
The prognostic value of both TAC and VAC considered as a con-
tinuous variable was further quantified and tested in univariate and
multivariate Cox regression analysis.
Several models were built according to the existent literature.
• Model 1 adjusted for age and gender.
• Model 2 adjusted for Logistic EuroSCORE.
• Model 3 adjusted for age, gender, diabetes, atrial fibrillation, coron-
ary artery disease, left ventricular ejection fraction (LVEF), and
renal function.
• Model 4 adjusted for age, gender, diabetes, atrial fibrillation, coron-
ary artery disease, LVEF, renal function, vascular access, and aortic
regurgitation.
• Model 5 adjusted for age, gender, diabetes, atrial fibrillation, coron-
ary artery disease, LVEF, renal function, vascular access, aortic re-
gurgitation, and TAC or VAC as applicable.
Figure 1 Example of calcifications measurement. Blue, yellow,
and orange are for valvular, ascending, and descending thoracic aor-
tic calcifications, respectively. Red calcifications do not belong to
the aorta and have been excluded.




























All analyses were performed using SPSS software, release 20.0.0




Table 1 summarizes the characteristics of the cohort according to
mean aortic gradient. Patients with LGAS were more prone to have
diabetes, atrial fibrillation, renal dysfunction, coronary artery disease,
lower LVEF, and higher logistic EuroSCORE (P<0.05 for all associa-
tions). HGAS patients experienced more procedural tamponade or
annulus rupture than LGAS patients (P=0.03).
Supplementary data online, Figure S1 displays the distributions of
TAC and VAC volumes among LGAS and HGAS patients. TAC was
higher in LGAS patients (P<0.001) compared with HGAS patients
while VAC was higher in HGAS compared to LGAS patients
(P=0.027).
Correlates of TAC AND VAC
Table 2 summarizes the correlates of TAC and VAC in univariate and
multivariate analyses.
....................................................................................................................................................................................................................
Table 1 Patient’s baseline and procedural characteristics according to mean aortic gradient
LGAS Gradient<40 mmHg HGAS Gradient40 mmHg P
Number of patients 435 961
Demographic characteristics
Age (years)a 82.7 (±7.5) 83.7 (±6.7) 0.01
Men, n (%) 267 (61.4%) 448 (46.6%) <0.001
BMI (kg/m2)a 26.1 (±4.7) 26.4 (±5.3) 0.3
Clinical history, n (%)
Diabetes 129 (29.7%) 232 (24.1%) 0.035
Hypertension 248 (71.7%) 589 (71.5%) 1
Smokers 66 (19%) 126 (15.2%) 0.1
Dyslipidaemia 180 (52%) 438 (53.2%) 0.7
Atrial fibrillation 159 (36.8%) 287 (30.2%) 0.018
CAD 222 (51.3%) 408 (42.5%) 0.002
PVD 110 (25.3%) 200 (20.8%) 0.07
Previous stroke or TIA 45 (10.4%) 79 (8.2%) 0.2
COPD 90 (20.7%) 176 (18.4%) 0.3
NYHA 3/4 268 (63.7%) 582 (61.8%) 0.5
TTE parameters
LVEF (%)a 51.3 (±16.1) 58.8 (±12.4) <0.001
LVEF <50%, n (%) 179 (41.3%) 196 (20.5%) <0.001
Mean aortic gradient (mmHg)a 30.3 (±6.6) 54.7 (±13.4) -
Aortic valve area (cm2)a 0.74 (±0.21) 0.63 (±0.17) <0.001
Aortic valve area (cm2/m2)a 0.42 (±0.12) 0.36 (±0.09) <0.001
Moderate/severe MR, n (%) 7 (1.6%) 10 (1.1%) 0.4
PASP (mmHg)a 43.7 (±15) 43.8 (± 14) 0.8
Renal function
GFR (mL/min/1.73 m2)a 47.6 (±21.3) 50.2 (±22.5) 0.05
Euroscorea
19.18 (±11.6) 16.77 (±9.79) <0.001
Procedural and hospitalization
Femoral access n (%) 306 (70.5%) 684 (71.3%) 0.7
Balloon expandable valve (n %) 278 (64.1%) 593 (68.1%) 0.2
Aortic Regurgitation >2 (n %) 3 (0.7%) 14 (1.5%) 0.3
Tamponade or annulus rupture (n%) 6 (1.4%) 33 (3.5%) 0.03
New pacemaker implantation 66 (18.6%) 136 (16.3%) 0.3
BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; HGAS, high-gradient aortic stenosis;
LGAS, low-gradient aortic stenosis; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York Heart Association; PASP, pulmonary artery systolic pres-
sure; PVD, peripheral vascular disease; TIA, transient ischaemic attack; TTE, transthoracic echography.
aValues are expressed as mean±SD or percentages.
Bold values P<0.005.


















In multivariate analyses, the correlates of TAC were age, gender,
hypertension, coronary artery disease, peripheral vascular disease,
and renal function, P<0.05 for all. In multivariate analyses, the corre-
lates of VAC were gender, mean aortic gradient, and to a lesser ex-
tent peripheral vascular disease, P<0.05 for all.
Prognostic value of TAC AND VAC
After 3 years of follow-up, 23 (1.6%) patients were lost to follow-up
and 245 (17.8%) patients experienced CV mortality, 92 (21.6%) in
LGAS patients, and 153 (16.2%) in HGAS patients, respectively,
pLogRank=0.018 (Figure 2).
Figure 3 displays the Kaplan–Meier curves according to the three
groups defined according to the terciles of TAC and VAC according
to mean aortic gradient. TAC ranges were 0–1.359 cm3 for Group 1,
1.36–3.616 cm3 for Group 2, and 3.619–22.33 cm3 for Group 3. VAC
ranges were 0–573.6 mm3 for Group 1, 573.7–1077 mm3 for Group
2, and 1078–4517.28 mm3 for Group 3. In LGAS patients, the survival
curves of the three groups defined according to terciles of TAC were
significantly different for CV mortality (pLogRank=0.007) (Figure 3A)
with a survival much lower for patients belonging to the third group;
conversely, no difference of the survival curves of the three groups
defined according to terciles of VAC (Figure 3B) was observed. In
HGAS, the survival curves of the three groups defined according to
terciles of both TAC and VAC were significantly different for CV
mortality (pLogRank=0.04 and 0.005, respectively) (Figure 3C and D).
Again the survival was lower for patients belonging to the third
groups defined according to terciles of TAC or VAC.
Table 3 summarizes univariate and multivariate Cox analyses in
LGAS and HGAS patients.
In LGAS patients, TAC was associated with CV mortality in uni-
variate analysis and in all multivariate models while VAC was not. In
HGAS patients, TAC remained only associated with CV mortality in
univariate analysis and after adjustment for age and gender but not in
other multivariate models, while VAC was associated with CV mor-
tality in univariate and in all multivariate models.
................................................................ ................................................................
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....................................................................................................................................................................................................................
Table 2 Correlates of TAC and VAC: univariate and multivariate linear regression analysis
Variables TAC VAC
Univariate Multivariate Univariate Multivariate
b P-value b P-value b P-value b P-value
Age (þ1year) 0.080 0.003 0.098 0.005 0.044 0.107
Gender (men) 0.082 0.002 0.090 0.004 0.234 <0.001 0.317 <0.001
Hypertension (yes) 0.174 <0.001 0.149 <0.001 -0.053 0.081
Diabetes (yes) 0.069 0.01 0.028 0.353 -0.071 0.011 -0.05 0.08
Dyslipidemia (yes) 0.085 0.004 0.051 0.102 0.025 0.417
Smoking (yes) 0.05 0.086 0.068 0.023 0.001 0.980
Coronary artery disease (yes) 0.150 <0.001 0.089 0.004 -0.043 0.118
Peripheral vascular disease (yes) 0.170 <0.001 0.123 <0.001 -0.061 0.028 -0.068 0.019
Atrial fibrillation (yes) 0.033 0.217 0.005 0.844
Estimated glomerular filtration rate (þ1 mL/min) -0.111 <0.001 -0.086 0.013 0.022 0.441
Left ventricular ejection fraction (þ1%) -0.028 0.290 -0.005 0.868
Aortic-valve area (þ1 cm2) 0.040 0.139 -0.096 0.001 -0.055 0.075
Mean aortic valve gradient (þ1 mmHg) -0.056 0.037 0.017 0.590 0.217 <0.001 <0.001
LogTAC (þ1 cm3) 0.022 0.435
LogVAC (þ1 mm3) 0.022 0.435
TAC, thoracic aorta calcifications; VAC, valvular aortic calcifications.
Bold values P<0.005.
Figure 2 Kaplan–Meier analysis of 3-year cardiovascular mortal-
ity-free survival according to according to mean aortic gradient.
HGAS, high-gradient aortic stenosis (mean aortic gradient
>_40 mmHg); LGAS, low-gradient aortic stenosis (mean aortic
gradient<40 mmHg).




































By considering the prognostic influence of VAC and TAC on post-
TAVI outcomes, we highlighted some pathophysiological differences
between LGAS and HGAS patients; while the prognosis of the clas-
sical HGAS form is mainly driven by valvular aspects, which of LGAS
is more complex, being related to vascular features. This explains, at
least in part, why both AS forms do not benefit to the same extent
from a TAVI procedure and suggest that TAC and VAC should be
considered for risk stratification.
This study confirms that LGAS and HGAS patients are different
with respect to some important clinical characteristics and comor-
bidities. LGAS also have a worse prognosis than HGAS after valve re-
placement in line with previous reports.12 The course of the disease
could be influenced by factors that may differ between LGAS and
HGAS patients. Traditional AS is characterized by a severe reduction
of aortic valve area, correlated to both a high VAC and a high gradi-
ent,3,4 as confirmed in this study. HGAS is an unequivocal valvular
disease as emphasized by the major prognostic significance of VAC in
this this situation. This is consistent with previously published studies
in patients with AS, treated by TAVI or surgery, demonstrating that
VAC was associated with mortality.13 The mechanisms underlying
the association of VAC with post-TAVI outcomes may be linked to
an increased rate of periprocedural complications, device failure,
pacemaker implantation, or paravalvular leak.14,15 AS severity, and
thus VAC, is also correlated with myocardial fibrosis,16 which is
mostly irreversible and influences post-operative mortality17 and
heart failure.18 This may explain that VAC continued to have a prog-
nostic significance over the long run, i.e. after AS relief.
In LGAS patients, TAC but not VAC represents a major risk factor
for CV mortality. Albeit TAC and VAC share some common path-
ways,19 both being linked with atherosclerotic risk factors, they are
not tightly related suggesting different significance. TAC seems more
integrative, being related to CV factors, CV disease, and renal func-
tion. In this respect, the prognostic impact of TAC in LGAS is in line
with a more diffuse disease encompassing cardiac, vascular, and
Figure 3 Kaplan–Meier analysis of 3-year cardiovascular mortality-free survival according to groups defined on terciles of TAC and VAC in LGAS
and HGAS patients. HGAS, high-gradient aortic stenosis (mean aortic gradient>_40 mmHg); LGAS, low-gradient aortic stenosis (mean aortic
gradient<40 mmHg); TAC, thoracic aortic calcifications; VAC, valvular aortic calcifications.




















































..kidney damages. Moreover, TAC represents a surrogate of vascular
afterload20; it has been shown that the negative prognosis impact of
an increased vascular load was even worse in the presence of low
LVEF or low stroke volume.5,6 In the setting of TAVI, the high residual
vascular load will continue to exert its detrimental influence on left
ventricular function over the long time.7,8,21 This is in line with a
lower left ventricle mass regression and a lower LVEF improvement
at 1-year follow-up in AS patients with a high calcification burden of
the thoracic aorta.22 TAC has recently been incorporated in a dedi-
cated TAVI risk score, the CAPRI score, that predicts 1-year mortal-
ity10 and hospitalization for heart failure.23. The fact that VAC was
not of prognostic importance in this setting, reinforces the view that,
valvular disorder is not the sole component of LGAS.
Clinical implications
The present multicentric study highlights the pathophysiological dif-
ferences existing between LGAS and HGAS patients. The pre-
TAVI CT-scan provides some crucial prognostic information by
quantifying the calcification load of both the thoracic aorta and the
valve. On top of these pathophysiological insights, this study has
important prognostic consequences. TAC may be crucial to con-
sider for risk stratification, particularly in the setting of LGAS to
foresee the post-TAVI outcome. On top of being associated with
peri-procedural complications, VAC will still influence outcome
after restoration of transvalvular flow in HGAS patients.
Nowadays, VAC and TAC are easily measurable with CT-scan,
and artificial intelligence will probably allow to fully automatize
their measurements as it is already the case for coronary calcifica-
tions. Therefore, together with other predictors of outcomes,
VAC and TAC may help in the decision-making process during the
TAVI work-up with the aim of selecting patients with a high prob-
ability of poor outcome after the procedure.
Limits
The present ancillary study of C4CAPRI study is a registry, even
though the completeness of data entered is high,10 we may not ex-
clude that some information may not have been available in the data-
base. For example, the repeatability of Doppler data was not assessed.
With the improvement of aortic valve bioprosthesis, and the evo-
lution of TAVI indications, the patients treated nowadays by TAVI
may not fully match in terms of risk with those included in the present
study, i.e. between 2010 and 2014, questioning the generalizability of
the study results. Still, valvular and aortic calcifications are common
findings in the AS setting and will still be encountered in lower risk
patients. VAC and left ventricle outflow tract calcifications have been
associated with more aortic regurgitation and more pacemaker im-
plantation after TAVI. While new generation prosthesis has partly
addressed these drawbacks, it is unlikely that their use would lessen
the prognostic significance of VAC; indeed the rate of aortic regurgi-
tation is already low in the study population, and, in any case, not dif-
ferent between the more calcified HGAS patients than in the LGAS
ones. Thresholds of VAC volume have been proposed in order to
stratify the severity of AS with a special attention to gender.
However, these thresholds have been determined on a different CT-
Scan protocol. In our work, the aim was not to define a threshold as
all patients were considered to have a severe AS. The aim was to
highlight the differential prognostic value of TAC and VAC in HGAS
and LGAS patients. It would have been interesting to assess the
..................................................................... ..................................................................
....................................................................................................................................................................................................................
Table 3 Risk of 3-year cardiovascular mortality in unadjusted and adjusted Cox regression models
LGAS (n5435) HGAS (n5961)
HR (95% CI) P HR (95% CI) P
TAC3aþ1 cm 1.078 (1.030–1.129) 0.001 1.052 (1.005–1.101) 0.028
VAC3aþ1 cm 0.788 (0.506–1.227) 0.291 1.299 (1.044–1.616) 0.019
TAC3bþ1 cm 1.097 (1.046–1.152) <0.001 1.049 (1.001–1.100) 0.044
VAC3bþ1 cm 0.703 (0.437–1.1290) 0.145 1.276 (1.010–1.612) 0.041
TAC3cþ1 cm 1.030 (1.014–1.047) <0.001 1.047 (1.000–1.097) 0.052
VAC3cþ1 cm 0.790 (0.511–1.220) 0.287 1.288 (1.033–1.606) 0.024
TAC3dþ1 cm 1.085 (1.024–1.149) 0.005 1.035 (0.981–1.091) 0.205
VAC3dþ1 cm 0.780 (0.478–1.273) 0.320 1.336 (1.048–1.703) 0.019
TAC3eþ1 cm 1.073 (1.010–1.141) 0.023 1.023 (0.966–1.083) 0.443
VAC3eþ1 cm 0.738 (0.447–1.218) 0.235 1.335 (1.031–1.728) 0.028
TAC3fþ1 cm 1.085 (1.019–1.156) 0.011 1.015 (0.955–1.079) 0.626
VAC3fþ1 cm 0.713 (0.439–1.8) 0.235 1.342 (1.034–1.742) 0.027
CI, confidence interval; HGAS, high-gradient aortic stenosis; HR, hazard ratio; LGAS, low-gradient aortic stenosis; TAC, thoracic aortic calcifications; VAC, valvular aortic
calcifications.
aUnadjusted.
bModel 1 adjusted for age and gender.
cModel 2 adjusted for Logistic EuroSCORE.
dModel 3 adjusted for: age, gender, diabetes, atrial fibrillation, coronary artery disease, left ventricular ejection fraction, renal function.
eModel 4 adjusted for: age, gender, diabetes, atrial fibrillation, coronary artery disease, left ventricular ejection fraction, renal function, vascular access (femoral Y N), aortic re-
gurgitation >2.
fModel 5 adjusted for model 4þTAC and VAC.
Bold values P<0.005.







































































..stroke volume index in order to better categorize LGAS patients;
however, in this study, we only have the LVEF which is to some ex-
tent a surrogate. Finally, a lack of statistical power in HGAS patients
(less events) may explain the absence of prognostic value of TAC in
the full adjusted model.
Conclusions
TAC and VAC should be carefully analysed and quantified during the
pre-TAVI CT-scan since they carry specific prognostic information in
LGAS and HGAS patients, corresponding to partly different underly-
ing pathological mechanisms.
Supplementary data
Supplementary data are available at European Heart Journal - Cardiovascular
Imaging online.
Data availability
Possible, please send an email to the corresponding author with the
purpose of your demand.
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